Heron Therapeutics, Inc. (HRTX)
After hours:
| Previous close | 2.7000 |
| Open | 2.7300 |
| Bid | 2.6800 x 4000 |
| Ask | 2.9300 x 1300 |
| Day's range | 2.7300 - 2.9700 |
| 52-week range | 2.1900 - 9.4500 |
| Volume | |
| Avg. volume | 2,582,290 |
| Market cap | 344.775M |
| Beta (5Y monthly) | 0.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2930 |
| Earnings date | 27 Feb 2023 - 03 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.42 |
- Simply Wall St.
The past three years for Heron Therapeutics (NASDAQ:HRTX) investors has not been profitable
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shareholders should be happy to see the share price up 12% in the last month...
- PR Newswire
Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today highlights progress in its acute care and oncology care franchises.
- PR Newswire
Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced the submission of a supplemental New Drug Application (sNDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution to support the proposed indication for greatly expanded use of ZYNRELEF in soft tissue and orthopedic surgical procedures and a newly passed congr
